Opzelura (Ruxolitinib 1.5% Cream) for Non-Segmental Vitiligo
Apply a thin layer of Opzelura twice daily to affected vitiligo areas covering up to 10% body surface area, with treatment potentially requiring more than 24 weeks for meaningful repigmentation. 1
Dosing and Application Instructions
Standard Dosing Regimen
- Apply twice daily (morning and evening) as a thin layer to all affected vitiligo areas
- Maximum coverage: Up to 10% body surface area 1
- Maximum weekly amount: Do not exceed one 60-gram tube per week or one 100-gram tube per 2 weeks 1
Application Technique
- Apply thin layer directly to depigmented patches
- For topical use only—not for ophthalmic, oral, or intravaginal use 1
- Can be applied to both facial and body lesions 2
Treatment Duration and Response Assessment
Satisfactory response may require treatment beyond 24 weeks. 1 The pivotal TRuE-V1 and TRuE-V2 trials demonstrated:
- At 24 weeks: 29.8-30.9% of patients achieved ≥75% facial repigmentation (F-VASI75) 2
- At 52 weeks: 50.3% of continuous users achieved F-VASI75 response 3
Re-evaluation Timeline
If the patient does not find repigmentation meaningful by 24 weeks, re-evaluate with the healthcare provider to determine whether to continue treatment. 1 However, given that responses continue to improve through 52 weeks, consider extending treatment beyond 24 weeks before discontinuation if some response is evident.
Monitoring Requirements
Clinical Monitoring
- Serial photographs every 2-3 months to objectively track repigmentation progress (extrapolated from phototherapy monitoring recommendations) 4
- Monitor for signs of infection during and after treatment 1
- Watch for herpes zoster reactivation 1
Laboratory Monitoring
- Complete blood count (CBC) as clinically indicated, particularly if signs/symptoms of thrombocytopenia, anemia, or neutropenia develop 1
- Consider baseline thyroid function testing given high prevalence of autoimmune thyroid disease in vitiligo patients 4
- No routine lipid monitoring specified for topical formulation (unlike oral JAK inhibitors) 1
Safety Surveillance
Monitor for development of:
- Application site reactions: Acne (6.3-6.6%), pruritus (5.3-5.4%), erythema (2%) 1
- Infections: Nasopharyngitis (4%), urinary tract infections (2%) 1
- Systemic symptoms: Headache (4%), pyrexia (1%) 1
Important Safety Considerations
Contraindications to Use
Avoid Opzelura in patients with:
- Active serious infections (including localized infections) 1
- History of thrombosis or at increased thrombotic risk 1
- Concurrent use with strong CYP3A4 inhibitors 1
Do Not Combine With:
- Therapeutic biologics
- Other JAK inhibitors
- Potent immunosuppressants (azathioprine, cyclosporine) 1
Patient Selection and Counseling
Ideal Candidates
- Patients ≥12 years of age with non-segmental vitiligo 1
- Depigmentation affecting ≤10% body surface area 1
- Efficacy demonstrated across all Fitzpatrick skin types, disease durations, and prior treatment statuses 3
Critical Patient Education
Inform patients about:
- Expected timeline: Meaningful repigmentation typically requires 6+ months of consistent twice-daily application 2
- Common side effects: Application site acne and itching are most frequent 1
- Serious risks: Though rare with topical use, educate about infection risk, cardiovascular events, and thrombosis symptoms 1
- Pregnancy: Report exposure to pregnancy registry (1-855-463-3463) 1
Clinical Pearls
Application site acne is the most common adverse event (6%) and typically mild-to-moderate in severity. 1 This can be managed with standard acne treatments without discontinuing Opzelura.
Responses vary by anatomical location—facial lesions typically respond better than acral sites (hands/feet), consistent with general vitiligo treatment patterns. 2
Continuous treatment through 52 weeks shows progressive improvement, with F-VASI75 response rates increasing from 30% at 24 weeks to 50% at 52 weeks. 2, 3 This supports extended treatment duration for partial responders.